{
    "clinical_study": {
        "@rank": "21813", 
        "arm_group": [
            {
                "arm_group_label": "Probiotic", 
                "arm_group_type": "Experimental", 
                "description": "Patients randomized to probiotic therapy will receive 1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis"
            }, 
            {
                "arm_group_label": "Sugar Pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Patients randomized to placebo therapy will receive an identical appearing placebo capsule on a twice-daily basis"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness of bacteria called Lactobacillus\n      GG, a Probiotic, in preventing the growth of resistant bacteria in the digestive tract in\n      patients on broad spectrum antimicrobials."
        }, 
        "brief_title": "Probiotics to Promote Intestinal Health", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Communicable Diseases", 
            "Infection", 
            "Anti-Infective Agents", 
            "Therapeutic Uses", 
            "Pharmacologic Actions"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Communicable Diseases", 
                "Infection"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults \u2265 18 years old\n\n          -  Admission to the non-ICU medical and surgical wards\n\n          -  On broad spectrum antimicrobials with an anticipated length of stay of >48 hours\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Non English speaking\n\n          -  Expected to die within 7 days\n\n          -  Unable or unwilling to consent\n\n          -  HIV infection with a CD4 count <200\n\n          -  Neutropenia with an absolute neutrophil count less than 500 cells/ml (or expected to\n             drop to less than 500)\n\n          -  Clinically significant diarrhea or history of C. difficile infection in the last 3\n             months\n\n          -  History of VRE colonization and/or infection in the last year\n\n          -  Transplant recipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "418", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02046512", 
            "org_study_id": "201310102", 
            "secondary_id": "CK000162-aim3"
        }, 
        "intervention": {
            "arm_group_label": "Probiotic", 
            "description": "1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis", 
            "intervention_name": "Probiotic", 
            "intervention_type": "Dietary Supplement", 
            "other_name": "Culturelle"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Probiotics", 
        "lastchanged_date": "January 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington University School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of Lactobacillus Rhamnosus GG to Promote Intestinal Health", 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Colonization of the gastrointestinal tract with C. difficile, vancomycin-resistant enterococci (VRE), multidrug-resistant Acinetobacter baumannii, and multidrug-resistant Pseudomonas. Colonization occurs when the subject acquires the above organism while in the study.", 
            "measure": "Change in the composition of the intestinal flora with a focus on multidrug-resistant organisms (MDRO) in the intention to treat population (ITT).", 
            "safety_issue": "No", 
            "time_frame": "Outcome will be measured every 3 days after enrollment, at the time of discharge, and at 60 days post-discharge"
        }, 
        "reference": [
            {
                "PMID": "22574332", 
                "citation": "Lucado J, Gould C, Elixhauser A. Clostridium Difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124. 2012 Jan. Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Health Care Policy and Research (US); 2006 Feb-. Available from http://www.ncbi.nlm.nih.gov/books/NBK92613/"
            }, 
            {
                "PMID": "22491338", 
                "citation": "Hall AJ, Curns AT, McDonald LC, Parashar UD, Lopman BA. The roles of Clostridium difficile and norovirus among gastroenteritis-associated deaths in the United States, 1999-2007. Clin Infect Dis. 2012 Jul;55(2):216-23. doi: 10.1093/cid/cis386. Epub 2012 Apr 4."
            }, 
            {
                "PMID": "21685488", 
                "citation": "Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2011 Sep;66(9):1963-71. doi: 10.1093/jac/dkr242. Epub 2011 Jun 18. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02046512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "collaborator": {
                "agency": "Centers for Disease Control and Prevention", 
                "agency_class": "U.S. Fed"
            }, 
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}